How do you pay?

How to pay the least

Ask for the cash price

Yuflyma

Yuflyma is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Yuflyma’s cash price, and one or two other pharmacies too.
  2. Yuflyma’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameYuflyma
Authorized genericadalimumab-aaty
Regular genericadalimumab-aaty
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone sold yet
Same as Yuflyma?
The original
–
–

Brand nameThe maker’s card

Celltrion CARES Co-pay Assistance Program

Savings card from Celltrion

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

Sign up on celltrionconnect.com 

Or call 1-877-812-6662.

In the maker’s words

“Under the Program, Eligible Patients may pay as little as $0 for Adalimumab-aaty for each dose.”

From the maker’s offer on celltrionconnect.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Yuflyma itself, from the same company, sold without the brand name, and usually for less. For now Yuflyma is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Yuflyma is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

YUFLYMA is a tumor necrosis factor (TNF) blocker indicated for:

  • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid arthritis.
  • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
  • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active p soriatic arthritis.
  • Reducing signs and symptoms in adult patients with active ankylosing spondylitis.
  • Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
  • Treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
  • Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
  • Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
  • Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.

Source: the FDA label for Yuflyma (CELLTRION USA, Inc.), July 15, 2026. Full label on DailyMed 

Good to know